Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

Emilie Cornec-Le Gall (1, 2) , Jaime D. Blais (3) , Maria V. Irazabal (2) , Olivier Devuyst (4) , Ron T. Gansevoort (5) , Ron D. Perrone (6) , Arlene B. Chapman (7) , Frank S. Czerwiec (3) , John Ouyang (3) , Christina M. Heyer (8) , Sarah R. Senum (8) , Yannick Le Meur (9, 1) , Vicente E. Torres (8) , Peter C. Harris (8)

1 CHRU - Service de néphrologie, dialyse et transplantation rénale
2 Mayo Clinic [Rochester]
3 Otsuka PDC, Rockville, MD, USA
4 UZH - Universität Zürich [Zürich] = University of Zurich
5 Department of Nephrology
6 Tufts University School of Medicine [Boston]
7 Section of Nephrology University of Chicago
8 Division of Nephrology and Hypertension
9 LBAI - Lymphocytes B, Autoimmunité et Immunothérapies

Domaines: Immunologie

Emilie Cornec-Le Gall, Jaime D. Blais, Maria V. Irazabal, Olivier Devuyst, Ron T. Gansevoort, et al.. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology Dialysis Transplantation, 2017, ⟨10.1093/ndt/gfx188⟩. ⟨hal-01567881⟩